Evidence map›Paper›PMID 34771679›Full record

ArticleCancers2021

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma.

Katia Todoerti, Domenica Ronchetti, Noemi Puccio, Ilaria Silvestris, Vanessa Favasuli, Nicola Amodio, Massimo Gentile, Fortunato Morabito, Antonino Neri, Elisa Taiana

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Long non‑coding RNAs in multiple myeloma (Review).International journal of oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Katia TodoertiDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Domenica RonchettiDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-4824-3445
Noemi PuccioDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-1016-3597
Ilaria SilvestrisDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Vanessa FavasuliDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.ORCID 0000-0001-6466-7961
Nicola AmodioDepartment of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.
Massimo GentileHematology Unit, "Annunziata" Hospital of Cosenza, 87100 Cosenza, Italy.
Fortunato MorabitoHematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem 91191, Israel.
Antonino NeriDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Elisa TaianaDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.ORCID 0000-0003-4940-1318
University of Milan · ITAzienda Ospedaliera di Cosenza · ITMagna Graecia University · ITOspedale Annunziata di Cosenza · IT

Funding

Italian Association for Cancer Research IG16722Italian Association for Cancer Research IG24365Italian Association for Cancer Research IG24449
6 · The paper itself

Abstract

The biological impact of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) is becoming an essential aspect of the investigation, which may contribute to understanding the disease's complex pathobiology, providing novel potential therapeutic targets. Herein, we investigated the expression pattern and the clinical relevance of the lncRNA MIAT in MM, taking advantage of the publicly available CoMMpass database. MIAT expression in MM is highly heterogeneous and significantly associated with specific molecular lesions frequently occurring in MM. Transcriptome analyses of MM PCs from patients included in the CoMMpass database indicated a potential involvement of MIAT in different signaling pathways and ribosome biogenesis and assembly. These findings suggest that MIAT deregulation may play a pathogenetic role in MM by affecting both proliferation pathways and, indirectly, the translational process. Although MIAT expression levels seem not to be significantly associated with clinical outcome in multivariate analyses, high MIAT expression levels are associated with bortezomib resistance, this suggesting that MIAT targeting could overcome drug resistance in MM. These findings strongly prompt for further studies investigating the significance of MIAT in MM.

Indexed as

bortezomibMIATmultiple myeloma

Identifiers

PMID34771679
PMCPMC8583301
OpenAlexW3210905339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.